Brian Jonas, MD, Discusses FDA Approval of Venclexta® for the Treatment of Newly Diagnosed AML.

Brian Jonas, MD, Discusses FDA Approval of Venclexta® for the Treatment of Newly Diagnosed AML.

Venclexta Data Positive for AMLПодробнее

Venclexta Data Positive for AML

Dr. DiNardo on the Rationale for the Pooled Analysis Evaluating Venetoclax in AMLПодробнее

Dr. DiNardo on the Rationale for the Pooled Analysis Evaluating Venetoclax in AML

Data on VENCLEXTA reinforcing the efficacyПодробнее

Data on VENCLEXTA reinforcing the efficacy

How have venetoclax combinations changed the way we treat AML?Подробнее

How have venetoclax combinations changed the way we treat AML?

The importance of venetoclax in newly diagnosed AMLПодробнее

The importance of venetoclax in newly diagnosed AML

Venetoclax for AMLПодробнее

Venetoclax for AML

Dr. Lai on the Potential Benefits of Venetoclax in AMLПодробнее

Dr. Lai on the Potential Benefits of Venetoclax in AML

Brian Jonas, ASCO20: Venetoclax combination treatment in older patients with acute myeloid leukemiaПодробнее

Brian Jonas, ASCO20: Venetoclax combination treatment in older patients with acute myeloid leukemia

Venetoclax-Based Combination Therapies Revolutionize Paradigm for Elderly AMLПодробнее

Venetoclax-Based Combination Therapies Revolutionize Paradigm for Elderly AML

Safety and efficacy of venetoclax-based regimens for AMLПодробнее

Safety and efficacy of venetoclax-based regimens for AML

Dr. Martin on FDA Approval of Denosumab in Multiple MyelomaПодробнее

Dr. Martin on FDA Approval of Denosumab in Multiple Myeloma

Venclexta - week 3.Подробнее

Venclexta - week 3.

The Benefits of Venetoclax in CLLПодробнее

The Benefits of Venetoclax in CLL

Insights into pemigatinib and the recent FDA approval of this agentПодробнее

Insights into pemigatinib and the recent FDA approval of this agent

New and Emerging AML Therapies Being Studied in Clinical TrialsПодробнее

New and Emerging AML Therapies Being Studied in Clinical Trials

Daniel DeAngelo, MD, PhD Discusses Acute Myeloid Leukemia (Full Interview)Подробнее

Daniel DeAngelo, MD, PhD Discusses Acute Myeloid Leukemia (Full Interview)

Venetoclax + azacitidine in unfit patients with AMLПодробнее

Venetoclax + azacitidine in unfit patients with AML

Venetoclax retreatment for CLLПодробнее

Venetoclax retreatment for CLL

Lachelle Weeks, MD, PhD, Leukemia Physician & Researcher | Dana-Farber Cancer InstituteПодробнее

Lachelle Weeks, MD, PhD, Leukemia Physician & Researcher | Dana-Farber Cancer Institute